HIGHLIGHTS
- who: HIV. and colleagues from the Division of Clinical Health Sciences, University of South Africa have published the article: ISSN: (Online) 2078-6751, (Print) 1608-9693, in the Journal: (JOURNAL)
- what: Dolutegravir exposure was marginally lower in participants with obesity, but this is not clinically significant given that trough concentrations were above a putative minimum effective concentration.
- how: The authors compared the pharmacokinetic parameters of dolutegravir administered in participants with and without obesity in Southern African PLWH enrolled in the ADVANCE randomised clinical trial. Similar observations were made in the Swiss HIV cohort . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.